跳到正文
原文
Nature 健康护理主题·· 4 天前AI 评分30

超罕见疾病药物开发模式:传统盈利模式难以为继,替代路径探索

Drug development models for ultra-rare disorders

AI 导读

传统营利模式难以支撑罕见及超罕见神经系统疾病的药物研发,需探索替代方案。文章讨论了多个可行项目与倡议,包括AAV基因治疗平台项目、FDA基于合理机制的罕见病指导原则应用,以及慈善资助与协作网络等新型研发路径。

正文
  • Comment
  • Published: 16 November 2026

Nature Reviews Neurology (2026) Cite this article

The traditional for-profit model of drug development is not sustainable for rare and ultra-rare neurological conditions, so alternative models are needed. Here, we consider some of the programmes and initiatives that are providing viable pathways.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

32.70 € / 30 days cancel any time

Learn more

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Yates, N. & Hinkel, J. The economics of moonshots: value in rare disease drug development. Clin. Transl. Sci. 15, 809–812 https://doi.org/10.1111/cts.13270 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Brooks, P. J. et al. The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases. Nat. Rev. Drug Discov. 23, 157–158 https://doi.org/10.1038/d41573-024-00020-8 (2024).

    Article  CAS  PubMed  Google Scholar 

  3. Brooks, P. J. et al. The Platform Vector Gene Therapies Project: increasing the efficiency of adeno-associated virus gene therapy clinical trial startup. Hum. Gene Ther. 31, 1034–1042 https://doi.org/10.1089/hum.2020.259 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hendry, C. & Zhou, J. & Jiang, Y.-h. Applying the FDA’s plausible mechanism guidance across the rare disease landscape. Nat. Genet. https://doi.org/10.1038/s41588-026-02750-4 (2026).

    Article  PubMed  Google Scholar 

  5. Karin, I., Büchner, B., Gauzy, F., Klucken, A. & Klopstock, T. Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON)—an international network on care and research for patients with neurodegeneration with brain iron accumulation (NBIA). Front. Neurol. 12, 642228 https://doi.org/10.3389/fneur.2021.642228 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Austin, C. P. et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin. Transl. Sci. 11, 21–27 https://doi.org/10.1111/cts.12500 (2018).

    Article  PubMed  Google Scholar 

  7. Hayflick, S. J. CoA-Z in pantothenate kinase-associated neurodegeneration (PKAN). ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04182763 (2025).

  8. A within-subject dose escalation study of a vitamin supplement for PKAN - PKAN-II. World Health Organization https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON55013 (2024).

  9. Majerol, M., Chaudhury, A., Traugott, C. & Mitta, V. The cell and gene therapy access model. JAMA 334, 1615–1616 https://doi.org/10.1001/jama.2025.16537 (2025).

    Article  PubMed  Google Scholar 

  10. Our venture philanthropy model. Cystic Fibrosis Foundation https://www.cff.org/about-us/our-venture-philanthropy-model (2024).

Download references

Author information

Authors and Affiliations

  1. Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR, USA

    Susan J. Hayflick

  2. Raiden Science Foundation, Beaverton, OR, USA

    Chris Andon

  3. Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands

    Antoinette D. I. van Asselt

  4. Innovation Center, University Medical Center Groningen, Groningen, Netherlands

    Harm Jan Hektor

  5. Department of Biomedical Sciences, European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, Netherlands

    Ody Sibon

Authors

  1. Susan J. Hayflick
  2. Chris Andon
  3. Antoinette D. I. van Asselt
  4. Harm Jan Hektor
  5. Ody Sibon

Corresponding author

Correspondence to Susan J. Hayflick.

Ethics declarations

Competing interests

S.J.H. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar. C.A. is an unpaid member of the Raiden Science Foundation. O.S. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar. H.J.H. is an unpaid member of the Spoonbill Foundation and Stichting Lepelaar.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hayflick, S.J., Andon, C., van Asselt, A.D.I. et al. Drug development models for ultra-rare disorders. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01295-8

Download citation

  • Published: 16 November 2026

  • Version of record: 16 November 2026

  • DOI: https://doi.org/10.1038/s41582-026-01295-8

来源:Nature 健康护理主题 · nature.com